In 2016, LEO Pharma’s revenue grew by 19% in local currencies to a record high of DKK 9,863 million against DKK 8,457 million in 2015 driven by strong performance of new and existing products. Revenue increased by 13% in region Europe, 39% in region international and 16% in region US in local currencies. Operating profit before depreciation, amortisation and impairment losses (EBITDA) totalled DKK 1,346 million. The year was marked by significant investments, leading to a decrease in operating profit (EBIT) to DKK 341 million from DKK 763 million in 2015 due to increased amortisation relating to investments. Net profit was 743 million against DKK 713 million in 2015.
Read the full story in the annual report news to the right and find the full annual report below.